{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:07:09Z","timestamp":1788242829184,"version":"build-2803163510"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K22CA241377"],"award-info":[{"award-number":["K22CA241377"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Since its introduction in the 1970s, endocrine therapy that targets the estrogen receptor alpha (ER\u03b1) signaling pathway has had tremendous success in the clinic in estrogen receptor positive (ER+) breast cancer. However, resistance to endocrine therapy eventually develops in virtually all patients with metastatic disease. Endocrine resistance is a primary unaddressed medical need for ER+ metastatic breast cancer patients. It has been shown that tumors become resistant through various mechanisms, converging on the acquisition of genetic alterations of ER, components of the MAP kinase pathway, or transcription factors (TFs). For instance, mutations in the human epidermal growth factor receptor-2 (HER2) lead to complete resistance to all current endocrine therapies including aromatase inhibitors, selective estrogen receptor modulators, and selective estrogen receptor degraders, as well as cross-resistance to CDK4\/6 inhibitors (CDK4\/6is). Emerging evidence points to an intriguing connection between endocrine-resistant tumors and the HER2-low subtype. Specifically, recent studies and our analysis of a publicly available breast cancer dataset both indicate that metastatic ER+ breast cancer with endocrine resistance conferred through acquired genetic alterations can often be classified as HER2-low rather than HER2-0\/HER2-negative. Limited data suggest that acquired endocrine resistance can also be accompanied by a subtype switch. Therefore, we suggest that there is an underappreciated association between the HER2-low subtype and endocrine resistance. In this perspective piece, we explore the evidence linking the HER2-low subtype with the various pathways to endocrine resistance and suggest that there are signaling networks in HER2-low tumors that intersect endocrine resistance and can be effectively targeted.<\/jats:p>","DOI":"10.3389\/fonc.2024.1461190","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:42:43Z","timestamp":1732257763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways"],"prefix":"10.3389","volume":"14","author":[{"given":"Gizem","family":"Yayli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Tokofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utthara","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01104-z","article-title":"Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas","volume":"14","author":"Berrino","year":"2022","journal-title":"Genome Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305226200","article-title":"Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation","volume":"278","author":"Martin","year":"2003","journal-title":"J Biol Chem"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220620","article-title":"Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells","volume":"144","author":"Knowlden","year":"2003","journal-title":"Endocrinology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0011-8","article-title":"Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant","volume":"114","author":"Frogne","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1755-8794-2-37","article-title":"Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer","volume":"2","author":"Loi","year":"2009","journal-title":"BMC Med Genomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.celrep.2018.07.009","article-title":"Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer","volume":"24","author":"Lei","year":"2018","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor-\u03b1: A novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","article-title":"Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations","volume":"33","author":"Jeselsohn","year":"2018","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1158\/2159-8290.CD-NB2021-0406","article-title":"Novel SERD has PFS edge against breast cancer","volume":"12","year":"2022","journal-title":"Cancer Discovery"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0287-5","article-title":"Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor\u2013directed therapies","volume":"51","author":"Nayar","year":"2019","journal-title":"Nat Genet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1544","article-title":"Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER+\/HER2 mutant breast cancer","volume":"25","author":"Croessmann","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signaling"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discovery"},{"key":"B30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10549-009-0334-0","article-title":"Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305","volume":"119","author":"Giordano","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O'Leary","year":"2018","journal-title":"Cancer Discovery"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1387","article-title":"ESR1 F404 mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer","volume":"14","author":"Kingston","year":"2024","journal-title":"Cancer Discovery"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792","article-title":"Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation","volume":"5","author":"Fanning","year":"2016","journal-title":"Elife"},{"key":"B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2005.05.008","article-title":"Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1","volume":"122","author":"Carroll","year":"2005","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ng.730","article-title":"FOXA1 is a key determinant of estrogen receptor function and endocrine response","volume":"43","author":"Hurtado","year":"2011","journal-title":"Nat Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature10730","article-title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","volume":"481","author":"Ross-Innes","year":"2012","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612835113","article-title":"FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer","volume":"113","author":"Fu","year":"2016","journal-title":"Proc Natl Acad Sci U States A"},{"key":"B40","doi-asserted-by":"publisher","first-page":"112821","DOI":"10.1016\/j.celrep.2023.112821","article-title":"High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer","volume":"42","author":"Fu","year":"2023","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ccell.2020.08.003","article-title":"FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer","volume":"38","author":"Arruabarrena-Aristorena","year":"2020","journal-title":"Cancer Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature22992","article-title":"Recurrent and functional regulatory mutations in breast cancer","volume":"547","author":"Rheinbay","year":"2017","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759577","article-title":"ARID1A mutation in metastatic breast cancer: A potential therapeutic target","volume":"11","author":"Cheng","year":"2021","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-019-0554-0","article-title":"ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer","volume":"52","author":"Xu","year":"2020","journal-title":"Nat Genet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1476-4598-13-239","article-title":"MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer","volume":"13","author":"Shajahan-Haq","year":"2014","journal-title":"Mol Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2567","article-title":"A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance","volume":"17","author":"Miller","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002987","article-title":"Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer","volume":"3","author":"Musgrove","year":"2008","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.8.4499","article-title":"c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry","volume":"18","author":"Prall","year":"1998","journal-title":"Mol Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00993","article-title":"Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E","author":"Butt","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4044","article-title":"Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance","volume":"26","author":"Pearson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3958","article-title":"Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER(+) metastatic breast cancer","volume":"26","author":"Mao","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discovery"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy497","article-title":"Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer","volume":"30","author":"Sokol","year":"2019","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discovery"},{"key":"B56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/2159-8290.CD-16-1431","article-title":"An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer","volume":"9","author":"Hanker","year":"2017","journal-title":"Cancer Discovery"},{"key":"B57","doi-asserted-by":"publisher","first-page":"P2","DOI":"10.1158\/1538-7445.SABCS22-P2-23-10","article-title":"Abstract P2-23-10: Gene expression and mutation profiles in HER2-mutated metastatic breast cancer","volume":"83","author":"Hensing","year":"2023","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/cancers11010074","article-title":"High frequency of ERBB2 activating mutations in invasive lobular breast carcinoma with pleomorphic features","volume":"11","author":"Rosa-Rosa","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3106","article-title":"Poziotinib inhibits HER2-mutant\u2013driven therapeutic resistance and multiorgan metastasis in breast cancer","volume":"82","author":"Kalra","year":"2022","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-024-45835-6","article-title":"Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial","volume":"15","author":"G\u00f3mez Tejeda Za\u00f1udo","year":"2024","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7993","article-title":"Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance","volume":"9","author":"Giltnane","year":"2017","journal-title":"Sci Trans Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"216968","DOI":"10.1016\/j.canlet.2024.216968","article-title":"EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4\/6 inhibitors in ER+ breast cancer","volume":"593","author":"Belli","year":"2024","journal-title":"Cancer letters"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1295","article-title":"A kinome-wide screen identifies the insulin\/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer","volume":"71","author":"Fox","year":"2011","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0247","article-title":"Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor","volume":"146","author":"Knowlden","year":"2005","journal-title":"Endocrinology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24831","article-title":"PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality","volume":"126","author":"L\u00f3pez-Knowles","year":"2010","journal-title":"Int J Cancer"},{"key":"B69","article-title":"PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer","volume":"11","author":"Huang","year":"2019","journal-title":"Am J Trans Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.025","article-title":"The association between Akt activation and resistance to hormone therapy in metastatic breast cancer","volume":"42","author":"Tokunaga","year":"2006","journal-title":"Eur J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/bcr569","article-title":"Akt kinases in breast cancer and the results of adjuvant therapy","volume":"5","author":"St\u00e5l","year":"2003","journal-title":"Breast Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600126","article-title":"Activation of AKT\/PKB in breast cancer predicts a worse outcome among endocrine treated patients","volume":"86","author":"P\u00e9rez-Tenorio","year":"2002","journal-title":"Br J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41698-023-00360-5","article-title":"AKT\/mTOR signaling modulates resistance to endocrine therapy and CDK4\/6 inhibition in metastatic breast cancers","volume":"7","author":"Abu-Khalaf","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","article-title":"Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models","volume":"13","author":"Rodriguez","year":"2023","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.21346","article-title":"The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients","volume":"13","author":"Tanic","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800296","article-title":"Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen","volume":"18","author":"Shoman","year":"2005","journal-title":"Mod Pathol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-014-0430-x","article-title":"Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase","volume":"16","author":"Fu","year":"2014","journal-title":"Breast Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"321","DOI":"10.20944\/preprints201902.0245.v1","article-title":"Updates on the CDK4\/6 inhibitory strategy and combinations in breast cancer","volume":"8","author":"Sobhani","year":"2019","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1530\/ERC-19-0501","article-title":"Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets","volume":"27","author":"Milioli","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"PD7","DOI":"10.1158\/1538-7445.SABCS20-PD7-08","article-title":"Abstract PD7-08: Igf1r mediates cdk4\/6 inhibitor (cdk4\/6i) resistance in tumor samples and in cellular models","volume":"81","author":"Wander","year":"2021","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0922","article-title":"Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatinib","volume":"2","author":"Prat","year":"2016","journal-title":"JAMA Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.3390\/ijms23137079","article-title":"Role of intrinsic subtype analysis with PAM50 in hormone receptors positive HER2 negative metastatic breast cancer: A systematic review","volume":"23","author":"Canino","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"GS2","DOI":"10.1158\/1538-7445.SABCS19-GS2-02","article-title":"Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state","volume":"80","author":"Cohen","year":"2020","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-020-0514-z","article-title":"Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance","volume":"22","author":"Bi","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0048","article-title":"Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management","volume":"13","author":"Guarneri","year":"2008","journal-title":"Oncologist"},{"key":"B86","doi-asserted-by":"publisher","first-page":"102496","DOI":"10.1016\/j.ctrv.2022.102496","article-title":"Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer","volume":"112","author":"Falato","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00337","article-title":"Frequent molecular subtype switching and gene expression alterations in lung and pleural metastasis from luminal A-type breast cancer","volume":"4","author":"Klebe","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the breast international group (BIG) molecular screening initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discovery"},{"key":"B89","doi-asserted-by":"publisher","first-page":"PO3","DOI":"10.1158\/1538-7445.SABCS23-PO3-16-04","article-title":"Abstract PO3-16-04: Distribution of intrinsic subtypes in endocrine-resistant and endocrine-sensitive breast cancer","volume":"84","author":"Schagerholm","year":"2024","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103619","article-title":"Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive\/HER2-low and HER2-0 breast cancer","volume":"9","author":"Schettini","year":"2024","journal-title":"ESMO Open"},{"key":"B91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41467-022-29498-9","article-title":"ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nature11143","article-title":"Whole-genome analysis informs breast cancer response to aromatase inhibition","volume":"486","author":"Ellis","year":"2012","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41467-019-14111-3","article-title":"Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade","volume":"11","author":"Bras\u00f3-Maristany","year":"2020","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"New Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/cas.2016.107.issue-7","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0900","article-title":"Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer","volume":"3","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3418","article-title":"The phase II mutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer","volume":"28","author":"Ma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discovery"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ Breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2\u2013 metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.c.7403517.v1","article-title":"Oral estrogen receptor PROTAC\u00ae vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00532","article-title":"A gene panel associated with abemaciclib utility in ESR1-mutated breast cancer after prior cyclin-dependent kinase 4\/6-inhibitor progression","volume":"7","author":"Brett","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"196ra99","DOI":"10.1126\/scitranslmed.3005747","article-title":"mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer","volume":"5","author":"Elkabets","year":"2013","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3025","article-title":"Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced\/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC)","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0541-5","article-title":"ARID1A influences HDAC1\/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response","volume":"52","author":"Nagarajan","year":"2020","journal-title":"Nat Genet"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0138","article-title":"FGFR1 amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR(+)) breast cancer","volume":"25","author":"Drago","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"20223","DOI":"10.1038\/s41598-023-46586-y","article-title":"Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer","volume":"13","author":"Saridogan","year":"2023","journal-title":"Sci Rep"},{"key":"B117","doi-asserted-by":"publisher","first-page":"RF01","DOI":"10.1158\/1538-7445.SABCS23-RF01-04","article-title":"Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced\/metastatic HR+\/HER2\u2013 breast cancer harboring high-level FGFR1 gene amplification","volume":"84","author":"Damodaran","year":"2024","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","article-title":"Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"13","author":"Coombes","year":"2022","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"RF02","DOI":"10.1158\/1538-7445.SABCS23-RF02-03","article-title":"Abstract RF02-03: Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced\/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08)","volume":"84","author":"Jhaveri","year":"2024","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.01.005","article-title":"Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2","volume":"17","author":"Hortobagyi","year":"2015","journal-title":"Neoplasia"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7949","article-title":"Evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 TBCRC041 randomized clinical trial","volume":"9","author":"Haddad","year":"2023","journal-title":"JAMA Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3008","article-title":"Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E\/d\/k\/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"40","author":"Meric-MBernstam","year":"2022","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.9051","article-title":"A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors","volume":"32","author":"Juric","year":"2014","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-3631","article-title":"Abstract 3631: Preclinical and clinical pharmacodynamic characterization of BBI-355, a novel, orally bioavailable, and selective CHK1 inhibitor being evaluated in the first-in-human Phase 1\/2 POTENTIATE clinical trial of patients with cancer harboring oncogene amplifications","volume":"84","author":"Liao","year":"2024","journal-title":"Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.012","article-title":"A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results","volume":"35","author":"Hamilton","year":"2024","journal-title":"Ann Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"17588359221083956","DOI":"10.1177\/17588359221083956","article-title":"AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+\/HER2- advanced breast cancer","volume":"14","author":"Bardia","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-OT2-07-01","article-title":"Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2)","volume":"80","author":"Turner","year":"2020","journal-title":"Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1164","article-title":"Lucitanib for the treatment of HR(+)\/HER2(-) metastatic breast cancer: results from the multicohort phase II FINESSE study","volume":"26","author":"Hui","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4375-5","article-title":"A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer","volume":"165","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.36_suppl.425082","article-title":"KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1002\/cam4.v9.14","article-title":"Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment","volume":"9","author":"Nogova","year":"2020","journal-title":"Cancer Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"OT2","DOI":"10.1158\/1538-7445.SABCS21-OT2-23-01","article-title":"Abstract OT2-23-01: A Phase 1b\/2a, open-label platform study to evaluate mirdametinib in combination with fulvestrant in ER+ metastatic breast cancers harboring MAPK-activating mutations","volume":"82","author":"Rosen","year":"2022","journal-title":"Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"Damodaran","year":"2022","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.breast.2020.04.004","article-title":"Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers","volume":"52","author":"Yi","year":"2020","journal-title":"Breast"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0963","article-title":"Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells","volume":"11","author":"Caldon","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2789-2","article-title":"Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers","volume":"143","author":"Sengupta","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.09.033","article-title":"Comprehensive molecular portraits of invasive lobular breast cancer","volume":"163","author":"Ciriello","year":"2015","journal-title":"Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1461190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T06:42:50Z","timestamp":1732257770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1461190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":138,"alternative-id":["10.3389\/fonc.2024.1461190"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1461190","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"article-number":"1461190"}}